Article
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, United States.
Journal of virological methods (impact factor:
2.13).
07/2009;
158(1-2):171-9.
DOI:10.1016/j.jviromet.2009.02.014
pp.171-9
Source: PubMed
-
Article: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
[show abstract] [hide abstract]
ABSTRACT: The few antibodies that can potently neutralize human immunodeficiency virus type 1 (HIV-1) recognize the limited number of envelope glycoprotein epitopes exposed on infectious virions. These native envelope glycoprotein complexes comprise three gp120 subunits noncovalently and weakly associated with three gp41 moieties. The individual subunits induce neutralizing antibodies inefficiently but raise many nonneutralizing antibodies. Consequently, recombinant envelope glycoproteins do not elicit strong antiviral antibody responses, particularly against primary HIV-1 isolates. To try to develop recombinant proteins that are better antigenic mimics of the native envelope glycoprotein complex, we have introduced a disulfide bond between the C-terminal region of gp120 and the immunodominant segment of the gp41 ectodomain. The resulting gp140 protein is processed efficiently, producing a properly folded envelope glycoprotein complex. The association of gp120 with gp41 is now stabilized by the supplementary intermolecular disulfide bond, which forms with approximately 50% efficiency. The gp140 protein has antigenic properties which resemble those of the virion-associated complex. This type of gp140 protein may be worth evaluating for immunogenicity as a component of a multivalent HIV-1 vaccine.Journal of Virology 02/2000; 74(2):627-43. · 5.40 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
anti-HIV-1 gp41 mAb 2F5
B cell repertoire
cloned EBV-transformed antibody-producing cell lines
defining anti-viral B cell repertoires
Defining human B cell repertoires
high-throughput analysis
high-throughput screening
Ig gene expression cassettes
Ig genes
Ig leader sequences
Ig-cloning step
IgG1 antibody
light-chain gene expression cassettes
light-chain variable regions
Novel linear Ig heavy-
rapid production
recombinant influenza mAbs
Single B cell sorting
single B cells
single human plasmablasts